Table 2 Baseline characteristics of 20 enrolled patients with COVID-19
Patient ID | Intervention group (n = 10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Survivors | Non-survivors | |||||||||
T1 | T2 | T5 | T7 | T10 | T3 | T4 | T6 | T8 | T9 | |
Age (years) | 40–49 | 50–59 | 50–59 | 40–49 | 70–79 | 70–79 | 30–39 | 70–79 | 70–79 | 60–69 |
Gender | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 1 | 1 |
Duration of Hospitalization | 10 | 80 | 6 | 9 | 6 | 11 | 4 | 9 | 15 | 16 |
Weight(kg) | 80 | 95 | 92 | 100 | 87 | 78 | 110 | 73 | 75 | 81 |
Underlying disease | DM | – | DM, ILD, HTN | IBS | HTN | DM | Sarcoidosis | – | Asthma, HT, HTN | HTN, RA |
Interval between ICU admission and cell injection (day) | 2 | 1 | 1 | 5 | 2 | 3 | 3 | 2 | 12 | 4 |
Interval between cell injection and discharge/death (day) | 6 | 78 | 4 | 3 | 3 | 5 | 1 | 6 | 0 | 11 |
Patient ID | Control group (n = 10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Survivors | Non-survivors | |||||||||
C3 | C5 | C7 | C9 | C10 | C1 | C2 | C4 | C6 | C8 | |
Age (years) | 80–89 | 70–79 | 70–79 | 60–69 | 30–39 | 30–39 | 50–59 | 60–69 | 50–59 | 70–79 |
Gender | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Duration of Hospitalization | 7 | 6 | 28 | 7 | 7 | 11 | 9 | 3 | 6 | 9 |
Weight(kg) | 65 | 70 | 75 | 85 | 90 | 104 | 90 | 69 | 80 | 100 |
Underlying disease | – | DM, HTN | Sarcoidosis, asthma, Liver Hemangioma | – | – | – | CKD | DM, HTN | HTN,DM | DM, HTN |
Interval between ICU admission and cell injection (day) | – | – | – | – | – | – | – | – | – | – |
Interval between cell injection and discharge/death (day) | – | – | – | – | – | – | – | – | – | – |